Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Gap Open @ C$ 1.86

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 13, 2024 6:18pm

79 Views

Post# 36177521

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Gap Open @ C$ 1.86

Sanofi is the only other recognizable/responsible company that had used PrECOG to run a clinical trial. Sanofi trialed their PARP inhibitor in TNBC. As mentioned on this message board many times, ONCY's pelareorep is synergistic with PARP inhibitors.

2023 paper : PARP inhibitors enhance reovirus-mediated cell killing through the deathinducing signaling complex (DISC) with an associated NF-κB-regulated immune response.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario